Beijing, China – From January 19 to January 21, Shanghai MicroPort Medical (Group) Co., Ltd. ("MicroPort®") attended the Ninth Clinical Cardiology Conference ("CCC2018") and the 15th Coronary Interventional Salon of China ("CISC2018") to display Firehawk® Rapamycin Target Eluting Coronary Stent System ("Firehawk®") and other innovative products as well as hosted a case competition focused on the treatment of complex lesion and CTO re-infarction.
During the case competition, Director Lianglong Chen of Fujian Medical University Union Hospital, Director Jinghua Liu of Beijing Anzhen Hospital, Director Hongliang Cong of Tianjin Chest Hospital, Director Jianping Luo of Beijing Jingmei Group General Hospital, and Professor Zhan Lv of Affiliated Hospital of North Sichuan Medical College were invited as guest speakers to review and moderate the cases. Two complex lesion cases, respectively presented by Director Liming Gao of Shanghai East Hospital and Director Yimin Wang of Linfen People's Hospital, shared the first place for their outstanding surgical skill and brilliant case review. Since 2016, MicroPort® hosted the case competition and has received positive feedback in various national-level congresses. The competition builds a communication platform between young physicians and top industry experts and creates new learning opportunities for primary physicians.
During the meeting, MicroPort® R&D staff exchanged ideas with Professor Shubin Qiao of Fuwai Hospital and Professor Dongxing Ma of Military General Hospital regarding Firefighter™ PTCA Balloon Catheter ("Firefighter™"). The two experts spoke highly of its excellent crossability and compliance. The R&D staff also discussed with the two experts about the clinical needs of left aurcle occlude and drug eluting balloon, and collected information regarding CTO technique strategies and complex, high-risk patients management, to lay a solid foundation for further optimization of product performance.
After 15 years of development, Coronary Interventional Salon of China has developed into a clinical cardiovascular congress covering various academic topics. Lei Jiang, MicroPort® First Vice President of Domestic Coronary Sales & Marketing, said: "We arranged such kind of academic events with the hope of showcasing the excellent performance of our coronary products while enhancing the communication with physicians to keep improving our products based on their clinical needs, and thereby promote the development of treatment technology in China's interventional cardiology and benefit more domestic patients."